H
Horst Lindhofer
Researcher at University of Hamburg
Publications - 106
Citations - 3670
Horst Lindhofer is an academic researcher from University of Hamburg. The author has contributed to research in topics: Catumaxomab & Trifunctional antibody. The author has an hindex of 28, co-authored 103 publications receiving 3404 citations.
Papers
More filters
Journal ArticleDOI
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Markus M. Heiss,Pawel Murawa,Piotr Koralewski,Elzbieta Kutarska,Olena O. Kolesnik,Vladimir V. Ivanchenko,Alexander S. Dudnichenko,Birute Aleknaviciene,Arturas Razbadauskas,Martin Gore,Elena Ganea-Motan,Tudor Ciuleanu,Pauline Wimberger,Alexander Schmittel,Barbara Schmalfeldt,Alexander Burges,Carsten Bokemeyer,Horst Lindhofer,Angelika Lahr,Simon L. Parsons +19 more
TL;DR: Catumaxomab showed a clear clinical benefit in patients with malignant ascites secondary to epithelial cancers, especially gastric cancer, with an acceptable safety profile.
Journal ArticleDOI
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
TL;DR: Catumaxomab is the first trAb and the first drug worldwide to be approved specifically for the treatment of MA and is in clinical trials in a number of other indications including ovarian and gastric cancer.
Journal ArticleDOI
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Alexander Burges,Pauline Wimberger,Carolin Kümper,Vera Gorbounova,Harald Sommer,Barbara Schmalfeldt,Jacobus Pfisterer,Michail Lichinitser,Anatoliy Makhson,Vladimir Moiseyenko,Angelika Lahr,Elisabeth Schulze,Michael Jäger,Michael A. Ströhlein,Markus M. Heiss,Thomas Gottwald,Horst Lindhofer,Rainer Kimmig +17 more
TL;DR: It is suggested that catumaxomab is a promising treatment option in ovarian cancer patients with malignant ascites because it prevented the accumulation of ascites and efficiently eliminated tumor cells with an acceptable safety profile.
Journal ArticleDOI
Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
Philipp Kiewe,Stephan Hasmüller,Steffen Kahlert,Maja Heinrigs,Brigitte Rack,Alexander Marmé,Agnieszka Korfel,Michael Jäger,Horst Lindhofer,Harald Sommer,Eckhard Thiel,Michael Untch +11 more
TL;DR: Treatment with triple infusions of ertumaxomab yields a strong immunologic response and measurements of cytokines suggest a strong T helper cell type 1–associated immune response.
Journal ArticleDOI
Structural and functional characterization of the trifunctional antibody catumaxomab.
Dirk Chelius,Peter Ruf,Patrick Gruber,Matthias Plöscher,Reinhard Liedtke,Eva Gansberger,Juergen Hess,Michael Wasiliu,Horst Lindhofer +8 more
TL;DR: Catumaxomab (Removab®) was launched in Europe for treatment of malignant ascites in April 2009 and the structural and functional characterization of this product is reported, including the presence of isoforms and aggregates.